FDA approves subcutaneous formulation of Actemra for use in active sJIA
Roche announced the FDA has approved the subcutaneous formulation of Actemra® (tocilizumab) for treatment of active systemic juvenile idiopathic arthritis in patients two years of age and older. Actemra can be given alone or in combination with methotrexate (MTX) in patients with sJIA. September 13, 2018